Last reviewed · How we verify
Yellow fever vaccine (live)
Yellow fever vaccine (live) is a live attenuated vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Prevention of yellow fever. Also known as: vYF vaccine, Stamaril vaccine, YF-VAX vaccine.
The live yellow fever vaccine stimulates an immune response by introducing a weakened form of the yellow fever virus, allowing the body to develop immunity.
The live yellow fever vaccine stimulates an immune response by introducing a weakened form of the yellow fever virus, allowing the body to develop immunity. Used for Prevention of yellow fever.
At a glance
| Generic name | Yellow fever vaccine (live) |
|---|---|
| Also known as | vYF vaccine, Stamaril vaccine, YF-VAX vaccine |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This is achieved through the replication of the vaccine virus in the body, which triggers an immune response and the production of antibodies and immune cells that can recognize and fight the yellow fever virus. The immune response is then maintained through the production of memory cells that can quickly respond to future infections.
Approved indications
- Prevention of yellow fever
Common side effects
- Injection site pain
- Fatigue
- Headache
Key clinical trials
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers (PHASE1)
- Phase 3 Single Arm, Open Study on vYF in Adults (PHASE3)
- Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults (PHASE3)
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (PHASE3)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
- Durability of Vaccine Responses (PHASE4)
- A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Yellow fever vaccine (live) CI brief — competitive landscape report
- Yellow fever vaccine (live) updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Yellow fever vaccine (live)
What is Yellow fever vaccine (live)?
How does Yellow fever vaccine (live) work?
What is Yellow fever vaccine (live) used for?
Who makes Yellow fever vaccine (live)?
Is Yellow fever vaccine (live) also known as anything else?
What drug class is Yellow fever vaccine (live) in?
What development phase is Yellow fever vaccine (live) in?
What are the side effects of Yellow fever vaccine (live)?
Related
- Drug class: All live attenuated vaccine drugs
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of yellow fever
- Also known as: vYF vaccine, Stamaril vaccine, YF-VAX vaccine
- Compare: Yellow fever vaccine (live) vs similar drugs
- Pricing: Yellow fever vaccine (live) cost, discount & access